Evidence map›Paper›PMID 23315797›Full record

ReviewAge and ageing2013

New horizons in the pathogenesis, diagnosis and management of sarcopenia.

Avan Aihie Sayer, Sian M Robinson, Harnish P Patel, Tea Shavlakadze, Cyrus Cooper, Miranda D Grounds

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Age and ageing, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Avan Aihie SayerAcademic Geriatric Medicine, University of Southampton, Southampton, UK. aas@mrc.soton.ac.uk
Sian M Robinson
Harnish P Patel
Tea Shavlakadze
Cyrus Cooper
Miranda D Grounds

Funding

Arthritis Research UK 13085Arthritis Research UK 13147Arthritis Research UK 13157Arthritis Research UK 13181Arthritis Research UK 13230Arthritis Research UK 16095Arthritis Research UK 16349Arthritis Research UK 17265Arthritis Research UK 17413Arthritis Research UK 17702Medical Research Council G0400491Medical Research Council MC_U147574215Medical Research Council MC_U147574217Medical Research Council MC_U147574218Medical Research Council MC_U147574221Medical Research Council MC_U147574233Medical Research Council MC_U147574236Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UP_A620_1015Medical Research Council MC_UU_12011/2Medical Research Council U.1475.00.002.00001.01(74218)Medical Research Council U.1475.00.003.00010.02(74237)Medical Research Council U.1475.00.003.00010.02(74238)Medical Research Council U.1475.00.003.00010.02(74242)
6 · The paper itself

Abstract

Sarcopenia is the age-related loss of skeletal muscle mass and function. It is now recognised as a major clinical problem for older people and research in the area is expanding exponentially. One of the most important recent developments has been convergence in the operational definition of sarcopenia combining measures of muscle mass and strength or physical performance. This has been accompanied by considerable progress in understanding of pathogenesis from animal models of sarcopenia. Well-described risk factors include age, gender and levels of physical activity and this knowledge is now being translated into effective management strategies including resistance exercise with recent interest in the additional role of nutritional intervention. Sarcopenia is currently a major focus for drug discovery and development although there remains debate about the best primary outcome measure for trials, and various promising avenues to date have proved unsatisfactory. The concept of 'new tricks for old drugs' is, however, promising, for example, there is some evidence that the angiotensin-converting enzyme inhibitors may improve physical performance. Future directions will include a deeper understanding of the molecular and cellular mechanisms of sarcopenia and the application of a lifecourse approach to understanding aetiology as well as to informing the optimal timing of interventions.

Indexed as

AgingAge FactorsAnimalsDietExerciseHumansMuscle, SkeletalMuscle StrengthNutritional StatusOrgan SizePrognosisRisk FactorsRisk Reduction BehaviorSarcopenia

Identifiers

PMID23315797
PMCPMC3575121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.